Cadence Capital Management LLC Buys New Holdings in Alexion Pharmaceuticals, Inc. (ALXN)

Cadence Capital Management LLC bought a new position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 6,001 shares of the biopharmaceutical company’s stock, valued at approximately $842,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Alexion Pharmaceuticals by 7.0% in the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock worth $2,424,428,000 after acquiring an additional 1,298,185 shares during the period. Vanguard Group Inc. raised its holdings in Alexion Pharmaceuticals by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock worth $1,798,992,000 after acquiring an additional 318,375 shares during the period. State Street Corp grew its position in Alexion Pharmaceuticals by 5.0% in the 2nd quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock worth $1,443,099,000 after purchasing an additional 561,962 shares during the last quarter. Ameriprise Financial Inc. grew its position in Alexion Pharmaceuticals by 3.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock worth $896,491,000 after purchasing an additional 215,005 shares during the last quarter. Finally, Jennison Associates LLC grew its position in Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. Hedge funds and other institutional investors own 94.16% of the company’s stock.

Several analysts have issued reports on ALXN shares. TheStreet lowered shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a research report on Tuesday, October 31st. Royal Bank Of Canada started coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target on the stock. Stifel Nicolaus decreased their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Finally, Leerink Swann restated an “outperform” rating and issued a $182.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $155.06.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $111.75 on Tuesday. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The firm has a market cap of $24,970.00, a PE ratio of 22.28, a PEG ratio of 1.19 and a beta of 1.18.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. During the same period in the previous year, the business earned $1.23 EPS. The firm’s revenue was up 7.5% on a year-over-year basis. analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Cadence Capital Management LLC Buys New Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/12/05/cadence-capital-management-llc-buys-new-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply